Page last updated: 2024-09-03

imatinib mesylate and Chronic Disease

imatinib mesylate has been researched along with Chronic Disease in 133 studies

Research

Studies (133)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	67 (50.38)	29.6817
2010's	44 (33.08)	24.3611
2020's	22 (16.54)	2.80

Authors

Authors	Studies
Baccarani, M; Efficace, F	1
Chan, CK; Mohamed, S; Szeto, SK; Tsang, CW	1
Agrawal, N; Ahmed, R; Bhurani, D; Hussain, S; Klugar, M; Sharma, M; Singh, AK	1
Adachi, K; Araki, M; Asada, S; Fukushima, T; Fukuyama, T; Goyama, S; Imai, M; Ito, R; Kitamura, T; Komatsu, N; Lamagna, C; Masuda, ES; Mikami, K; Morishita, S; Nagata, M; Takaku, T; Takeda, R; Takizawa, H; Tamura, M; Tanaka, Y; Tsuchiya, S; Umemoto, T; Watanabe, N	1
Beg, MMA; Guru, SA; Koner, BC; Mir, R; Saxena, A; Sumi, MP	1
Akıncı, S; Bakanay, ŞM; Çavdarlı, B; Ceran, F; Dağdaş, S; Dilek, İ; Falay, M; Gündüz, M; Korkmaz, G; Özet, G; Uçar, MA	1
Ciaffaglione, V; Consoli, V; Floresta, G; Greish, K; Intagliata, S; Marrazzo, A; Pittalà, V; Rescifina, A; Romeo, G; Salerno, L; Sorrenti, V; Vanella, L	1
Antunes, MV; de Souza Guterres, F; Fogliatto, LM; Kohlrausch, R; Krützmann, ME; Linden, R; Martini, RR; Mattevi, VS; Torriani, MS; Wagner, SC	1
Itoh, Y; Nakamura, Y; Wakimoto, N	1
Balabanov, S; Cantoni, N; Kahn, S; Kulenkampff, E; Lambert, JF; Schmidt, A; Seitz, P; Sommavilla, R; Zenhaeusern, R	1
Aizuddin, AN; Mohamad Selamat, E; Sathar, J; Tumian, NR; Wan Puteh, SE	1
Ross, DM	1
Czerwińska-Rybak, J; Gil, L; Jarmuż-Szymczak, M; Kanduła, Z; Lewandowski, K; Przybyłowicz-Chalecka, A; Ratajczak, B; Ustaszewski, A	1
Abduljalil, O; Gerbitz, A; Kim, DDH; Kumar, R; Lam, W; Law, A; Linn, SM; Lipton, J; Mattsson, J; Michelis, FV; Novitzky-Basso, I; Pasic, I; Viswabandya, A	1
Alsuliman, T; Beauvais, D; Coiteux, V; Gauthier, J; Lionet, A; Magro, L; Srour, M; Yakoub-Agha, I	1
Baird, K; Booher, S; Comis, LE; Cowen, EW; Ho, PS; Joe, GO; Mitchell, SA; Pavletic, SZ; Rosenthal, EA	1
Chen, L; Chen, Y; Guo, J; Li, W; Meng, L; Wang, H; Xiong, Y; Yin, H	1
Buxhofer-Ausch, V; Cejka, D; Enkner, W; Kranewitter, W; Thiem, U; Webersinke, G	1
Costello, PN; Krishnan, K; Manthri, S	1
Gong, SJ; Hong, MH; Kashif, A; Kim, G; Kim, IS; Lee, JS; Lee, MS; Lee, NR; Nam, AR; Seok, PR; Song, IC; Sung, KH; Yang, SJ	1
Gao, X; Huang, X; Joshi, N; Luo, L; Shamseddine, N	1
Bermudez, A; Costilla Barriga, L; Ferrá Coll, C; López Corral, L; Lopez Godino, O; Márquez-Malaver, F; Martín, G; Martinez, C; Móles-Poveda, P; Ortí, G; Parra Salinas, I; Rifon, J; Zudaire Ripa, MT	1
Li, T; Lin, H; Liu, M; Wu, B; Zhong, H	1
Botella-Estrada, R; de Unamuno, B; Molés-Poveda, P; Montesinos, P; Piñana, JL; Sahuquillo, A; Sanz-Caballer, J	1
Ferrándiz-Pulido, C	1
Ankathil, R; Azlan, H; Baba, AA; Elias, MH	1
Ai, XF; Fang, LW; Hu, NB; Jia, YJ; Li, B; Liu, JQ; Pan, LJ; Qin, TJ; Qu, SQ; Ru, K; Xiao, ZJ; Xu, ZF; Zhang, HL; Zhang, Y	1
Asou, N; Fujioka, I; Fujita, H; Hatta, Y; Iriyama, N; Ishikawa, M; Kawaguchi, T; Kimura, Y; Kizaki, M; Komatsu, N; Nakazato, T; Sato, E; Sugimoto, KJ; Takaku, T; Tokuhira, M	1
Cong, Y; Li, C; Lin, H; Wang, R; Zhang, C	1
Beadling, C; Collichio, FA; Corless, CL; Demetri, GD; Ernstoff, MS; Fisher, DE; Flaherty, KT; Fletcher, JA; Friedlander, P; Gajewski, TF; Giobbie-Hurder, A; Gonzalez, R; Heinrich, MC; Hodi, FS; Kim, KB; Lawrence, D; Luke, JJ; Marino-Enriquez, A; O'Day, SJ; Van den Abbeele, AD; Weber, JS; Yap, JT; Zhu, M; Zukotynski, KA	1
Kawachi, H; Khadzhynov, D; Loof, T; Mika, A; Neumayer, HH; Peters, H; Wang-Rosenke, Y	1
Bacigalupo, A; Bresciani, P; Cimminiello, M; Coluzzi, S; Corradini, P; Fedele, R; Gabrielli, A; Leoni, P; Mordini, N; Nuccorini, R; Olivieri, A; Olivieri, J; Onida, F; Pane, F; Pascale, S; Patriarca, F; Pavone, E; Poloni, A; Selleri, C; Svegliati, S	1
Chen, L; Dea, K; Goldberg, SL; Guérin, A; Wu, EQ	1
Cross, NC; Erben, P; Fabarius, A; Gosenca, D; Haferlach, C; Haferlach, T; Hofmann, WK; Kellert, B; Kneba, M; Metzgeroth, G; Reiter, A; Scheid, C; Schwaab, J; Seifarth, W; Töpelt, K	1
Alimena, G; Breccia, M; Carmosino, I; Finsinger, P; Latagliata, R; Molica, M; Montagna, C; Romano, A; Salaroli, A; Santopietro, M; Serrao, A; Volpicelli, P; Vozella, F; Zacheo, I	1
Betticher, DC; Cornea, MI; Levrat, E; Pugin, P	1
Altamura, HK; Branford, S; Feng, J; Geoghegan, J; Hahn, CN; Holloway, MR; Moore, S; Nicola, M; Ross, DM; Schreiber, AW; Scott, HS; Yeoman, AL	1
Bron, D; Cordier, JF; Cottin, V; Heimann, P; Lambert, F; Roufosse, F; Sidon, P	1
Steiner, DJ	1
Appell, KC; Beasley, JR; Carroll, CD; Lin, T; Rokosz, LL; Webb, ML; Zhao, J	1
Apperley, JF; Bua, M; de Lavallade, H; Goldman, JM; Kaeda, J; Khorashad, JS; Marin, D; Milojkovic, D; Olavarria, E; Reid, AG; Szydlo, R	1
Chen, SJ; Chen, Z; Fu, JF; Hu, J; Jin, J; Li, JM; Pan, Q; Shi, JY; Wang, LN; Zhao, WL	1
Alexandrescu, DT; Dasanu, CA; Farzanmehr, H; Kauffman, L	1
Carreras, E; Fernández-Avilés, F; Martínez, C; Mascaró, JM; Moreno-Romero, JA; Rovira, M	1
Kobayashi, M; Kubota, T; Taguchi, H; Uemura, Y	1
Moretti, L; Salemi, S; Scapozza, L; Schmid, I; Simon, D; Simon, HU; Yousefi, S	1
Apostolidis, J; Baltadakis, I; Evangelou, K; Gorgoulis, VG; Harhalakis, N; Karakasis, D; Papadakis, V; Sfikakis, PP	1
Cowen, EW	1
Catteau, B; Chevallier, P; Coiteux, V; Jouet, JP; Magro, L; Mohty, M; Terriou, L; Yakoub-Agha, I	1
Dührsen, U; Ebeling, P; Jansen, JH; Khandanpour, C; Mahlmann, S; Möröy, T; van der Reijden, BA; Vassen, L	1
Armbrust, T; Cameron, S; Füzesi, L; Gunawan, B; Langer, C; Ramadori, G; Sobotta, M	1
Chan, AL; Hsieh, HJ; Lin, SJ	1
Breitscheidel, L	1
Cancelas, JA; Rothenberg, ME; Yamada, Y	1
Cools, J; Lierman, E	1
Ahlborn, R; Buchholz, S; Diedrich, H; Eder, M; Ganser, A; Kamal, H; Stadler, M	1
Asou, H; Iwato, K; Kimura, A; Tanaka, H	1
Dengler, TJ; Hardt, SE; Katus, HA; Lossnitzer, D; Perz, JB; Volz, HC; Weiss, C; Zankl, AR	1
Brisou, P; Cournac, JM; de Jaureguiberry, JP; Martinaud, C; Ménard, G; Pons, S; Souraud, JB	1
Matsui, T; Sada, A	1
Feng, YQ; Li, X; Liu, J; Lü, S; Luo, Q; Wang, F; Wu, J; Xiong, S	1
Barker, B; Moudgil, H; Slocombe, G; Srinivasan, K	1
Li, Q; Li, Z; Lu, Q; Tse, W; Yang, R; Yuan, R; Zhao, J	1
Cioch, M; Dmoszynska, A; Helbig, G; Hus, M; Kata, D; Kozinska, J; Kyrcz-Krzemien, S; Morawska, M; Szczepanska-Szerej, H; Wieczorek, P; Woźniak, M	1
Burbury, K; Catalano, A; Chew, LP; Seymour, JF; Westerman, D	1
Koskinen, PK; Rintala, JM; Rintala, SE; Savikko, J; von Willebrand, E	1
Kang, JY; Kim, JS; Kim, JW; Kim, SC; Kim, SJ; Kim, YK; Kwon, SS; Lee, SY; Park, CK; Park, SH; Rhee, CK	1
Całbecka, M; Helbig, G; Hus, M; Kyrcz-Krzemień, S; Moskwa, A; Piszcz, J; Raźny, M; Rodzaj, M; Seferyńska, I; Swiderska, A; Urbanowicz, A; Żuk, E	1
Du, W; Miharu, M; Osumi, T; Shimada, H; Takahashi, T; Tanaka, R	1
Martínez, C	1
Rudzki, J; Wolf, D	1
Arnautovic-Custovic, A; Hasic, S; Jahic, A; Jovic, S; Kopic, E	1
Cross, NC; Erben, P; Hochhaus, A; Hofmann, WK; Klippstein, T; Martin, H; Metzgeroth, G; Mousset, S; Reiter, A; Teichmann, M; Walz, C	1
Harada, H; Harada, Y; Imagawa, J; Kimura, A; Matsumoto, K; Morita, K; Tarutani, M; Yoshida, T	1
Arai, S; Chen, GL; Cheng, EC; Flowers, ME; Johnston, LJ; McMillan, A; Miklos, DB; Otani, JM; Qiu, J; Shizuru, JA	1
Awano, N; Kitamura, S; Ryu, T; Takazoe, M; Tanaka, M; Yoshimura, N	1
Arnan, M; Duarte, RF; Manresa, F; Ortí, G; Peralta, T; Sánchez-Ortega, I; Servitje, O	1
Brosa, M; Crespo, C; Pérez-Simón, JA; Rodríguez, JM; Sierra, J	1
Burge, S; Peniket, A; Rodgers, CJ; Scarisbrick, J	1
Dees, C; Del Galdo, F; Distler, A; Distler, JH; Distler, O; Egberts, F; Palumbo-Zerr, K; Schett, G; Spriewald, BM; Tinazzi, I; Tomcik, M; Vollath, S; Zerr, P	1
Ahn, HS; Kang, HJ; Kim, H; Kim, MS; Kim, NH; Lee, JW; Park, KD; Shin, HY	1
Adès, L; Bagot, M; Bouaziz, JD; Bourhis, JH; Dalle, JH; de Masson, A; Micol, JB; Nguyen, S; Peffault de Latour, R; Ribaud, P; Robin, M; Rubio, MT; Rybojad, M; Socié, G; Suarez, F; Wittnebel, S; Xhaard, A; Yakouben, K	1
Abolfazli, R; Harirchian, MH; Siroos, B	1
Albitar, M; Andreeff, M; Beran, M; Capdeville, R; Cortes, JE; Faderl, S; Freireich, EJ; Garcia-Manero, G; Giles, FJ; Hayes, K; Issa, JP; Kantarjian, HM; Keating, M; Koller, C; Kornblau, SM; O'Brien, S; Resta, D; Rios, MB; Shan, J; Smith, TL; Talpaz, M; Thomas, DA	1
Alomar, A; Puig, L; Sureda, A; Vidal, D	1
Galietta, A; Gambacorti-Passerini, CB; Gunby, RH; Piazza, R; Rostagno, R; Scapozza, L	1
Christoforidis, JB; D'Amico, DJ; DeAngelo, DJ	1
Savikko, J; Taskinen, E; Von Willebrand, E	1
Albitar, M; Colburn, DE; Cortes, JE; Giles, FJ; Kantarjian, HM; O'Brien, SM; Tsimberidou, AM; Verstovsek, S; Welch, MA	1
Berger, U; Hehlmann, R; Hochhaus, A; Lengfelder, E; Reiter, A	1
Coutré, S; Gotlib, J	1
Baccarani, M; Malagola, M; Martinelli, G; Ottaviani, E; Piccaluga, PP; Ricci, P; Rondoni, M; Visani, G	1
Popat, U; Rice, L	1
Jones, RL; Judson, IR	1
Ballard, EE; Skrepnek, GH	1
Chng, WJ; Tan, LH	1
Cools, J	2
Caplan, SN; Fetni, R; Johnson, NA	1
Odenike, O; Tefferi, A	1
Békassy, AN; De Bont, ES; Gadner, H; Gschaidmeier, H; Guilhot, F; Guilhot, J; Leblanc, T; Millot, F; Nelken, B; Stary, J; Sufliarska, S; Suttorp, M	1
Charlanne, H; Prin, L	1
Helbig, G; Hołowiecki, J; Stella-Hołowiecka, B	1
Fujita, H; Kurata, M; Maeda, A; Matsui, T; Matsushita, A; Nagai, K; Sada, A; Takahashi, T; Tanaka, Y; Togami, K; Watanabe, N	1
Berlin, AA; Hogaboam, CM; Lukacs, NW	1
Cabello, P; Cesar, JM; Ferro, T; Navarro, JL	1
Gotoh, M; Kawasugi, K; Noguchi, M; Shirafuji, N; Shirasaki, R; Tashiro, H	1
Cross, NC; Curtis, C; Erben, P; Haferlach, T; Hehlmann, R; Hochhaus, A; Lengfelder, E; Metzgeroth, G; Müller, MC; Reiter, A; Schnittger, S; Schoch, C; Schultheis, B; Walz, C	1
Augustson, B; Cannell, P; Joske, D; Willson, A	1
Apperley, JF; Khorashad, JS; Marin, D; Olavarria, E; Perz, JB	1
Di Stefano, F	1
Campos, L; Cornillon, J; Delabesse, E; Flandrin, P; Mauvieux, L; Morel, S; Nadal, N; Olaru, D	1
Arai, Y; Eguchi, M; Eguchi-Ishimae, M; Maki, K; Mitani, K; Nakamura, Y; Sasaki, K; Tadokoro, J; Tokita, K	1
Beacci, D; Chase, A; Cools, J; Crescenzi, B; Cross, NC; Gallì, A; Jones, AV; Martelli, MF; Marynen, P; Mecucci, C; Rosti, V; Specchia, G; Starza, RL; Vandenberghe, P	1
Apperley, J; Brito-Babapulle, F; Cilloni, D; Cross, NC; Erben, P; Gottardi, E; Grimwade, D; Hehlmann, R; Hochhaus, A; Jovanovic, JV; Martinelli, G; Metzgeroth, G; Ottaviani, E; Popp, H; Preudhomme, C; Reiter, A; Roche-Lestienne, C; Rondoni, M; Saglio, G; Score, J; Solomon, E; Waghorn, K; Walz, C	1
Bona, R; Kaplan, AA; Shafique, S	1
Buitenhuis, M; Coffer, PJ; Cools, J; Verhagen, LP	1
Cross, NC; Curtis, CE; George, J; Grand, FH; Sahoo, TP; Waghorn, K	1
Ma, ES; Siu, LL; Wong, CL; Wong, KF	1
Cross, NC; Erben, P; Hensel, M; Ho, AD; Hochhaus, A; Jones, AV; Krämer, A; Kruth, J; Müller, M; Reiter, A	1
Albano, F; Anelli, L; La Starza, R; Liso, V; Lonoce, A; Rocchi, M; Specchia, G; Zagaria, A	1
Arai, A; Miyamura, K; Motomura, S; Usui, N; Yokoyama, M	1
Baccarani, M; Cortes, J; Deininger, MW; Druker, BJ; Fischer, T; Gambacorti-Passerini, C; Gathmann, I; Goldman, JM; Guilhot, F; Hochhaus, A; Kantarjian, H; Niederwieser, D; Paquette, R; Park, B; Smith, D; So, C; Stone, R	1
Dunbar, CE; Fay, MP; Fu, W; Hartsell, M; Klion, AD; Law, MA; Lemery, S; Maric, I; Noel, P; Nutman, TB; Robyn, J; Schmid, L; Talar-Williams, C	1
Alimena, G; Bhalla, K; Bhatia, R; Cervantes, F; Gattermann, N; Giles, F; Haque, A; Hochhaus, A; Kantarjian, HM; le Coutre, P; Litzow, M; Nicolini, FE; O'Brien, SG; Ossenkoppele, GJ; Palandri, F; Resta, DJ; Shou, Y; Weitzman, A	1
Cervantes, F	1
Chen, F; Hou, M; Ji, C; Li, L; Sun, J; Wang, W; Yan, S; Zhang, C; Zhang, M	1
Arai, A; Hayashi, S; Inazawa, J; Miura, O; Wakabayashi, S; Yan, W	1
Corm, S; Deluche, L; Geffroy, S; Joha, S; Laï, JL; Nicolini, FE; Philippe, N; Preudhomme, C; Roche-Lestienne, C; Tigaud, I	1
Salemi, S; Simon, D; Simon, HU; Yousefi, S	1
Całbecka, M; Gajkowska, J; Grzegorczyk, J; Helbig, G; Hołowiecki, J; Klimkiewicz, R; Lewandowska, M; Majewski, M; Moskwa, A; Stella-Hołowiecka, B	1
Araki, N; Iyama, S; Kobune, M; Matsunaga, T; Murase, K; Niitsu, Y; Sagawa, T; Sato, T; Takayama, T; Takimoto, R	1

Reviews

16 review(s) available for imatinib mesylate and Chronic Disease

Article	Year
Impact of imatinib treatment on renal function in chronic myeloid leukaemia patients. Nephrology (Carlton, Vic.), 2022, Volume: 27, Issue:4 Topics: Chronic Disease; Humans; Imatinib Mesylate; Kidney; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors	2022
Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges. Expert opinion on therapeutic targets, 2008, Volume: 12, Issue:7 Topics: Animals; Benzamides; Chronic Disease; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Immune System Diseases; Inflammation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2008
Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia. International archives of allergy and immunology, 2009, Volume: 149 Suppl 1 Topics: Animals; Benzamides; Chronic Disease; Disease Models, Animal; Eosinophils; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Mastocytosis; Mice; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction	2009
Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia. Expert review of anticancer therapy, 2009, Volume: 9, Issue:9 Topics: Antineoplastic Agents; Benzamides; Chronic Disease; Drug Delivery Systems; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interleukin-5; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2009
[Clinical manifestations and treatment of chronic eosinophilic leukemia (CEL)/idiopathic hypereosinophilic syndrome (HES) in Japan]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2010, Volume: 51, Issue:7 Topics: Antineoplastic Agents; Benzamides; Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recombinant Fusion Proteins; Reference Standards	2010
[Treatment of chronic graft-versus-host disease with protein tyrosine kinase inhibitors]. Methods and findings in experimental and clinical pharmacology, 2010, Volume: 32 Suppl A Topics: Adrenal Cortex Hormones; Animals; Benzamides; Calcineurin Inhibitors; Chronic Disease; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Transplantation, Homologous; Treatment Outcome	2010
More than skin deep? Emerging therapies for chronic cutaneous GVHD. Bone marrow transplantation, 2013, Volume: 48, Issue:3 Topics: Antibodies, Monoclonal, Murine-Derived; Benzamides; Chronic Disease; Graft vs Host Disease; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Rituximab; Skin Diseases; Ultraviolet Therapy	2013
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. The Lancet. Oncology, 2003, Volume: 4, Issue:2 Topics: Acute Disease; Animals; Antineoplastic Agents; Benzamides; Chronic Disease; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Amplification; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines	2003
Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Seminars in cancer biology, 2004, Volume: 14, Issue:4 Topics: Animals; Antineoplastic Agents; Benzamides; Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2004
The development and application of imatinib. Expert opinion on drug safety, 2005, Volume: 4, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chronic Disease; Dermatofibrosarcoma; Gastrointestinal Stromal Tumors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines	2005
FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia. Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie, 2005, Volume: 67, Issue:3 Topics: Antineoplastic Agents; Benzamides; Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2005
Conventional and new treatment options for myelofibrosis with myeloid metaplasia. Seminars in oncology, 2005, Volume: 32, Issue:4 Topics: Androgens; Angiogenesis Inhibitors; Antineoplastic Agents; Azacitidine; Benzamides; Chronic Disease; Decitabine; Erythropoietin; Humans; Imatinib Mesylate; Piperazines; Primary Myelofibrosis; Pyrimidines; Quinolones; Recombinant Proteins	2005
[Treatment of hypereosinophilia]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:1 Pt 2 Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Benzamides; Chronic Disease; Cyclosporins; Drug Resistance; Eosinophilia; Glucocorticoids; Humans; Hydroxyurea; Imatinib Mesylate; Immunologic Factors; Immunosuppressive Agents; Interferon-alpha; Myeloproliferative Disorders; Parasitic Diseases; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Time Factors	2006
[Oncogene Fip1-likeL/PDGFRalpha as a target for imatinib in patients with hypereosinophilic syndrome and chronic eosinophilic leukemia. A novel look at pathogenesis and therapy]. Polskie Archiwum Medycyny Wewnetrznej, 2005, Volume: 113, Issue:5 Topics: Algorithms; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Chronic Disease; Dose-Response Relationship, Drug; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2005
Myelofibrosis: biology and treatment options. European journal of haematology. Supplementum, 2007, Issue:68 Topics: Benzamides; Chronic Disease; Darbepoetin alfa; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Piperazines; Primary Myelofibrosis; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Recombinant Proteins; Splenectomy; Thalidomide	2007
Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity. International journal of hematology, 2007, Volume: 86, Issue:3 Topics: Adult; Antineoplastic Agents; Benzamides; Biopsy; Chemical and Drug Induced Liver Injury; Chromosomes, Human, Pair 4; Chronic Disease; Exons; Female; Furosemide; Glucocorticoids; Heart Diseases; Heart Ventricles; Hepatocytes; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Introns; Liver Diseases; Lymphocytes; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Necrosis; Oncogene Proteins, Fusion; Piperazines; Prednisolone; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sequence Deletion; Sodium Potassium Chloride Symporter Inhibitors; Thrombosis	2007

Trials

12 trial(s) available for imatinib mesylate and Chronic Disease

Article	Year
Smoking influences the outcomes of patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia in the chronic phase: A retrospective analysis. Hematological oncology, 2019, Volume: 37, Issue:3 Topics: Aged; Chronic Disease; Databases, Factual; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies; Smoking; Survival Rate	2019
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-10, Volume: 31, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Chronic Disease; Female; Gene Amplification; GTP Phosphohydrolases; Humans; Imatinib Mesylate; Male; Melanoma; Membrane Proteins; Middle Aged; Mucous Membrane; Mutation; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Sunlight; Survival Rate	2013
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood, 2013, Dec-12, Volume: 122, Issue:25 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Autoantibodies; Benzamides; Chronic Disease; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Lymphoproliferative Disorders; Male; Middle Aged; Monitoring, Physiologic; Myeloproliferative Disorders; Piperazines; Prednisolone; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Severity of Illness Index; Survival Rate; Time Factors	2013
Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease. Blood, 2009, Oct-22, Volume: 114, Issue:17 Topics: Adult; Benzamides; Chronic Disease; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Lung Diseases; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Treatment Outcome; Young Adult	2009
A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood, 2011, Oct-13, Volume: 118, Issue:15 Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal; Benzamides; Chronic Disease; Disease-Free Survival; Drug Resistance; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2011
Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:2 Topics: Adult; Benzamides; Bone Marrow Transplantation; Chronic Disease; Dasatinib; Drug Resistance; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Sclerosis; Skin Diseases; Thiazoles; Transplantation, Homologous	2012
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:7 Topics: Benzamides; Chronic Disease; Cytogenetic Analysis; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Treatment Failure; Treatment Outcome	2002
Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia, 2006, Volume: 20, Issue:2 Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Chronic Disease; Drug Administration Schedule; Europe; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Recurrence; Remission Induction; Stem Cell Transplantation; Survival Rate; Treatment Outcome	2006
Molecular analysis of chronic eosinophilic leukemia with t(4;10) showing good response to imatinib mesylate. International journal of hematology, 2006, Volume: 83, Issue:5 Topics: Adult; Asian People; Benzamides; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 4; Chronic Disease; Enzyme Activation; Eosinophilia; Follow-Up Studies; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Time Factors; Translocation, Genetic	2006
Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood, 2007, Nov-15, Volume: 110, Issue:10 Topics: Adult; Antineoplastic Agents; Benzamides; Biomarkers, Pharmacological; Biopsy; Chronic Disease; Dose-Response Relationship, Drug; Drug Dosage Calculations; Eosinophils; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Remission Induction; Withholding Treatment	2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood, 2007, Nov-15, Volume: 110, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chronic Disease; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome	2007
A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. British journal of haematology, 2008, Volume: 141, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers; Chronic Disease; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Treatment Outcome	2008

Other Studies

105 other study(ies) available for imatinib mesylate and Chronic Disease

Article	Year
Quality of Life Improvements in Patients With Chronic Myeloid Leukemia After Stopping Long-Term Therapy: Who Can Benefit the Most? Journal of the National Cancer Institute, 2022, 01-11, Volume: 114, Issue:1 Topics: Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Quality of Life	2022
Massive retinal infiltrates as the presenting sign of chronic myeloid leukemia: Clinical and imaging features of leukemic retinopathy. European journal of ophthalmology, 2023, Volume: 33, Issue:1 Topics: Animals; Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Retina; Retinal Diseases; Retinal Hemorrhage; Vision Disorders	2023
Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors. Nature communications, 2022, 01-12, Volume: 13, Issue:1 Topics: Animals; Antineoplastic Agents; Chronic Disease; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immune Checkpoint Inhibitors; Interleukin-1 Receptor-Associated Kinases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Mice; Middle Aged; Neoplastic Stem Cells; Protein Kinase Inhibitors	2022
Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival. BMC cancer, 2022, Apr-14, Volume: 22, Issue:1 Topics: Apoptosis; Cell Cycle; Chronic Disease; Cytokines; Disease Progression; DNA; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Surveys and Questionnaires; Tumor Suppressor Protein p14ARF	2022
Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of Turkish journal of haematology : official journal of Turkish Society of Haematology, 2022, 08-25, Volume: 39, Issue:3 Topics: Chronic Disease; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Retrospective Studies	2022
Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia. Molecules (Basel, Switzerland), 2022, May-18, Volume: 27, Issue:10 Topics: Chronic Disease; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Protein Kinase Inhibitors	2022
Volumetric dried blood microsampling for monitoring imatinib mesylate therapy: Method development and clinical application in patients with chronic myeloid leukemia. Journal of pharmaceutical and biomedical analysis, 2023, Jan-05, Volume: 222 Topics: Adult; Child; Chromatography, Liquid; Chronic Disease; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Tandem Mass Spectrometry	2023
Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia. International journal of hematology, 2023, Volume: 117, Issue:4 Topics: Adrenal Cortex Hormones; Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prednisolone; Protein Kinase Inhibitors; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia	2023
A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia. BMC cancer, 2022, Nov-19, Volume: 22, Issue:1 Topics: Chronic Disease; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies; Switzerland	2022
Inequality in Drug Utilization among Chronic Myeloid Leukaemia Patients in Malaysia: A Cost-Utility Analysis. Asian Pacific journal of cancer prevention : APJCP, 2022, Dec-01, Volume: 23, Issue:12 Topics: Antineoplastic Agents; Chronic Disease; Cost-Benefit Analysis; Dasatinib; Drug Utilization; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Malaysia; Protein Kinase Inhibitors; Pyrimidines; Quality of Life	2022
Single cells tell multiple tales in CML. Blood, 2023, 06-01, Volume: 141, Issue:22 Topics: Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid	2023
The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure. Leukemia research, 2023, Volume: 132 Topics: Chromosome Aberrations; Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Treatment Failure; Treatment Outcome; Tyrosine Kinase Inhibitors	2023
A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment Outcomes. Hematology/oncology and stem cell therapy, 2023, Jul-20, Volume: 17, Issue:1 Topics: Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Retrospective Studies; Treatment Outcome	2023
The concurrent administration of imatinib with extracorporeal photopheresis leads to complete and durable responses in patients with refractory sclerotic type chronic graft-versus-host disease. Current research in translational medicine, 2020, Volume: 68, Issue:2 Topics: Adrenal Cortex Hormones; Adult; Chronic Disease; Combined Modality Therapy; Drug Resistance; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Immunosuppressive Agents; Male; Methoxsalen; Middle Aged; Photopheresis; Photosensitizing Agents; Protein Kinase Inhibitors; Retrospective Studies; Sclerosis; Treatment Outcome; Young Adult	2020
Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020, Volume: 28, Issue:8 Topics: Adolescent; Adult; Child; Chronic Disease; Clinical Trials, Phase II as Topic; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Motor Skills; Quality of Life; Sclerosis; Young Adult	2020
Feasibility Study of Switching to Nilotinib After First-line Imatinib in the Chronic Phase of Chronic Myeloid Leukemia. Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Feasibility Studies; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies	2020
Successful kidney transplantation in a patient with pre-existing chronic myeloid leukemia treated with imatinib. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2021, Volume: 21, Issue:1 Topics: Antineoplastic Agents; Benzamides; Chronic Disease; Humans; Imatinib Mesylate; Kidney Transplantation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2021
Chronic mast cell leukaemia with exon 9 BMJ case reports, 2020, Aug-24, Volume: 13, Issue:8 Topics: Antineoplastic Agents; Chronic Disease; Exons; Humans; Imatinib Mesylate; Leukemia, Mast-Cell; Male; Middle Aged; Mutation; Proto-Oncogene Proteins c-kit; Treatment Outcome	2020
S100A8 and S100A9 Promote Apoptosis of Chronic Eosinophilic Leukemia Cells. Frontiers in immunology, 2020, Volume: 11 Topics: Animals; Apoptosis; Calgranulin A; Calgranulin B; Cell Line, Tumor; Cells, Cultured; Chronic Disease; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Mice; Mitochondria; Models, Biological; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Recombinant Proteins	2020
Continuation of systemic treatments and outcomes for patients with chronic graft-versus-host disease in the USA. Immunotherapy, 2021, Volume: 13, Issue:5 Topics: Adult; Chronic Disease; Female; Graft vs Host Disease; Health Care Costs; Health Resources; Humans; Imatinib Mesylate; Insurance Claim Review; Male; Medication Adherence; Middle Aged; MTOR Inhibitors; Outcome Assessment, Health Care; Photopheresis; Retrospective Studies; Time-to-Treatment; United States	2021
Treatment of steroid-refractory chronic graft-versus-host disease with imatinib: Real-life experience of the Spanish group of hematopoietic transplantation (GETH). Clinical transplantation, 2021, Volume: 35, Issue:5 Topics: Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Retrospective Studies; Steroids	2021
An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article. Medicine, 2017, Volume: 96, Issue:29 Topics: Antineoplastic Agents; China; Chronic Disease; Cost-Benefit Analysis; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Health Care Costs; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Markov Chains; Models, Economic; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Treatment Outcome	2017
Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective. Actas dermo-sifiliograficas, 2018, Volume: 109, Issue:3 Topics: Adolescent; Adult; Chronic Disease; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies; Scleroderma, Localized; Treatment Outcome; Young Adult	2018
Imatinib: A New Tool for the Management of Chronic Sclerodermatous Graft-Vs-Host Disease. Actas dermo-sifiliograficas, 2018, Volume: 109, Issue:3 Topics: Chronic Disease; Graft vs Host Disease; Humans; Imatinib Mesylate; Scleroderma, Localized	2018
Aberrant DNA Methylation of SOCS1 Gene is Not Associated with Resistance to Imatinib Mesylate among Chronic Myeloid Leukemia Patients. Cardiovascular & hematological disorders drug targets, 2018, Volume: 18, Issue:3 Topics: Chronic Disease; DNA Methylation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myeloid; Promoter Regions, Genetic; Suppressor of Cytokine Signaling 1 Protein	2018
[Targeted sequencing analysis of hyper-eosinophilic syndrome and chronic eosinophilic leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2018, Jun-14, Volume: 39, Issue:6 Topics: Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta	2018
Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia. Medicine, 2019, Volume: 98, Issue:15 Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Chronic Disease; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Time Factors; Transcription, Genetic	2019
Tyrosine kinases inhibition by Imatinib slows progression in chronic anti-thy1 glomerulosclerosis of the rat. BMC nephrology, 2013, Oct-14, Volume: 14 Topics: Animals; Benzamides; Chronic Disease; Disease Progression; Glomerulonephritis, Membranoproliferative; Imatinib Mesylate; Male; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Rats; Rats, Wistar; Thy-1 Antigens; Treatment Outcome	2013
Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Current medical research and opinion, 2014, Volume: 30, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chronic Disease; Cohort Studies; Drug Monitoring; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies	2014
Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms. Genes, chromosomes & cancer, 2014, Volume: 53, Issue:5 Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 5; Chronic Disease; DNA-Binding Proteins; Eosinophilia; Gene Fusion; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia; Male; Microfilament Proteins; Molecular Sequence Data; Myeloproliferative Disorders; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Translocation, Genetic	2014
Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib. American journal of hematology, 2015, Volume: 90, Issue:2 Topics: Adult; Aged; Anemia; Antineoplastic Agents; Benzamides; Chronic Disease; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Reticulocytes; Severity of Illness Index; Sex Factors; Survival Analysis	2015
BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report. Journal of medical case reports, 2015, Apr-08, Volume: 9 Topics: Aged; Chronic Disease; Diagnosis, Differential; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Polycythemia; Polycythemia Vera; Protein Kinase Inhibitors	2015
Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene. Leukemia, 2016, Volume: 30, Issue:6 Topics: Aged; Antineoplastic Agents, Immunological; Chronic Disease; Delayed Diagnosis; DNA-Binding Proteins; Gene Fusion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-sis	2016
Severe Prolonged Cough as Presenting Manifestation of FIP1L1-PDGFRA+ Chronic Eosinophilic Leukaemia: A Widely Ignored Association. Respiration; international review of thoracic diseases, 2016, Volume: 91, Issue:5 Topics: Aged; Antineoplastic Agents; Chronic Disease; Cough; Delayed Diagnosis; Diagnosis, Differential; DNA-Binding Proteins; Gene Fusion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia; Lung; Male; mRNA Cleavage and Polyadenylation Factors; Real-Time Polymerase Chain Reaction; Receptor, Platelet-Derived Growth Factor alpha; Tomography, X-Ray Computed; Transcription Factors	2016
Pharmaceuticals and Medical Devices: Cost Savings. Issue brief (Health Policy Tracking Service), 2016, Dec-27, Volume: 2016 Topics: Anticonvulsants; Biological Products; Biosimilar Pharmaceuticals; Canada; Centers for Medicare and Medicaid Services, U.S.; Chronic Disease; Commerce; Cost Savings; Deductibles and Coinsurance; Drug Approval; Drug Costs; Drugs, Generic; Economics, Pharmaceutical; Epinephrine; Financial Audit; Humans; Imatinib Mesylate; Insurance Benefits; Insurance Coverage; Insurance, Pharmaceutical Services; Legislation, Drug; Medication Adherence; Medication Therapy Management; Naloxone; Pharmacies; State Government; Therapeutic Equivalency; United States; United States Food and Drug Administration	2016
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-10, Volume: 26, Issue:29 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Chronic Disease; Disease Progression; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Phosphotransferases; Piperazines; Protein Structure, Tertiary; Pyrimidines	2008
FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib. Chinese medical journal, 2008, May-20, Volume: 121, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Chronic Disease; Disease Progression; Female; fms-Like Tyrosine Kinase 3; Genotype; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins v-abl; Oncogene Proteins, Fusion; Phenotype; Piperazines; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction	2008
Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. Dermatology online journal, 2008, Jul-15, Volume: 14, Issue:7 Topics: Benzamides; Biopsy, Needle; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Hyperpigmentation; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Neoplasm Staging; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Risk Assessment	2008
Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease. Archives of dermatology, 2008, Volume: 144, Issue:9 Topics: Adolescent; Benzamides; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Localized	2008
A case of hypereosinophilic syndrome presenting with chronic cough successfully treated with imatinib. Respirology (Carlton, Vic.), 2009, Volume: 14, Issue:2 Topics: Adult; Benzamides; Chronic Disease; Cough; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2009
A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. Allergy, 2009, Volume: 64, Issue:6 Topics: Amino Acid Sequence; Benzamides; Benzenesulfonates; Chronic Disease; Drug Resistance; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Molecular Sequence Data; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib	2009
Is imatinib mesylate a promising drug in scleroderma due to extensive chronic graft-versus-host disease? Leukemia & lymphoma, 2009, Volume: 50, Issue:3 Topics: Benzamides; Chronic Disease; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Scleroderma, Systemic; Treatment Outcome	2009
A call for more dermatologic input into chronic graft-vs-host disease clinical trials. Archives of dermatology, 2009, Volume: 145, Issue:3 Topics: Benzamides; Chronic Disease; Clinical Trials as Topic; Dermatology; Graft vs Host Disease; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Localized; Skin Diseases	2009
Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood, 2009, Jul-16, Volume: 114, Issue:3 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Benzamides; Child, Preschool; Chronic Disease; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Retrospective Studies; Salvage Therapy; Sclerosis; Young Adult	2009
Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are highly expressed in patients with acute and chronic leukemia. International journal of hematology, 2009, Volume: 89, Issue:4 Topics: Acute Disease; Alternative Splicing; Animals; Antineoplastic Agents; Benzamides; Chlorocebus aethiops; Chronic Disease; COS Cells; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Pyrimidines; RNA, Messenger; Transcription Factors; Zinc Finger Protein GLI1	2009
Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? - single center experience. European journal of gastroenterology & hepatology, 2009, Volume: 21, Issue:7 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chronic Disease; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Receptors, Amino Acid; Receptors, Platelet-Derived Growth Factor; Survival Analysis; Treatment Outcome	2009
Stevens-Johnson syndrome induced by combination of imatinib and allopurinol. Chemotherapy, 2009, Volume: 55, Issue:4 Topics: Aged, 80 and over; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chronic Disease; Female; Humans; Imatinib Mesylate; Kidney Failure, Chronic; Leukemia, Myeloid; Piperazines; Pyrimidines; Stevens-Johnson Syndrome	2009
Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia. Journal of medical economics, 2008, Volume: 11, Issue:4 Topics: Adult; Antineoplastic Agents; Benzamides; Chronic Disease; Cost-Benefit Analysis; Germany; Humans; Imatinib Mesylate; Leukemia, Myeloid; Markov Chains; Piperazines; Pyrimidines; Quality-Adjusted Life Years; Stem Cell Transplantation; Transplantation, Homologous; Young Adult	2008
Pure red cell aplasia associated with imatinib-treated FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Internal medicine (Tokyo, Japan), 2010, Volume: 49, Issue:12 Topics: Adult; Benzamides; Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Red-Cell Aplasia, Pure	2010
Complete reversal of left ventricular mass in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia after therapy with imatinib. International journal of cardiology, 2011, Sep-15, Volume: 151, Issue:3 Topics: Adult; Benzamides; Chronic Disease; Humans; Hypereosinophilic Syndrome; Hypertrophy, Left Ventricular; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2011
[Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome]. La Revue de medecine interne, 2011, Volume: 32, Issue:5 Topics: Antineoplastic Agents; Benzamides; Chronic Disease; Gene Rearrangement, T-Lymphocyte; Genetic Testing; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; T-Lymphocytes; Treatment Outcome	2011
Inhibitor screening of protein kinases using MALDI-TOF MS combined with separation and enrichment of phosphopeptides by TiO2 nanoparticle deposited capillary column. The Analyst, 2010, Volume: 135, Issue:11 Topics: Antineoplastic Agents; Benzamides; Chronic Disease; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Leukemia, Myeloid; Nanoparticles; Phosphopeptides; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Titanium	2010
Persistent cough: an unusual cause. Idiopathic hypereosinophilic syndrome (HES). Thorax, 2010, Volume: 65, Issue:11 Topics: Benzamides; Chronic Disease; Cough; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tomography, X-Ray Computed	2010
Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3-PDGFRB fusion. Pediatric blood & cancer, 2011, Volume: 56, Issue:3 Topics: Adult; Antineoplastic Agents; Benzamides; Child; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 5; Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Translocation, Genetic; Treatment Outcome; Tropomyosin	2011
Rapid reversal of quadraparesis in chronic eosinophilic leukaemia expressing the FIP1L1-PDGFRA transcript after therapy with imatinib. Leukemia research, 2011, Volume: 35, Issue:3 Topics: Adult; Antineoplastic Agents; Benzamides; Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Magnetic Resonance Imaging; Male; mRNA Cleavage and Polyadenylation Factors; Piperazines; Pyrimidines; Quadriplegia; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger	2011
Concomitant FIP1L1-PDGFRA fusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib. Leukemia & lymphoma, 2011, Volume: 52, Issue:2 Topics: Aged; Antineoplastic Agents; Benzamides; Cell Lineage; Chronic Disease; Clone Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, T-Cell; Male; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2011
Early short-term imatinib treatment is sufficient to prevent the development of chronic allograft nephropathy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2011, Volume: 26, Issue:9 Topics: Animals; Antineoplastic Agents; Benzamides; Chronic Disease; Cyclosporine; Imatinib Mesylate; Immunoenzyme Techniques; Immunosuppressive Agents; Kidney Diseases; Kidney Transplantation; Male; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Rats; Rats, Inbred Strains; Time Factors; Transplantation, Homologous	2011
Effect of imatinib on airway smooth muscle thickening in a murine model of chronic asthma. International archives of allergy and immunology, 2011, Volume: 155, Issue:3 Topics: Airway Remodeling; Animals; Asthma; Benzamides; Chronic Disease; Female; Imatinib Mesylate; Interleukins; Mice; Mice, Inbred BALB C; Muscle, Smooth; Ovalbumin; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Severity of Illness Index; Stem Cell Factor; Transforming Growth Factor beta1	2011
Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chronic Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Retrospective Studies; Splenomegaly; Time Factors; Young Adult	2011
Imatinib is effective for prevention and improvement of fibrotic fasciitis as a manifestation of chronic GVHD. Bone marrow transplantation, 2012, Volume: 47, Issue:1 Topics: Adolescent; Benzamides; Bone Marrow Transplantation; Chronic Disease; Fasciitis; Fibrosis; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Transplantation, Homologous	2012
Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable? Expert review of hematology, 2011, Volume: 4, Issue:2 Topics: Antineoplastic Agents; Benzamides; Chronic Disease; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2011
Myeloprolipherative disorder type chronic myeloid leukemia--eosinophilic form. Medicinski arhiv, 2011, Volume: 65, Issue:3 Topics: Adult; Antineoplastic Agents; Benzamides; Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Piperazines; Pyrimidines	2011
Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia, 2012, Volume: 26, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Chronic Disease; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib	2012
[Successful treatment with low-dose dasatinib in a patient with chronic eosinophilic leukemia intolerant to imatinib]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2011, Volume: 52, Issue:7 Topics: Aged; Benzamides; Chronic Disease; Dasatinib; Drug Monitoring; Drug Tolerance; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Molecular Targeted Therapy; mRNA Cleavage and Polyadenylation Factors; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Thiazoles; Treatment Outcome	2011
Successful treatment of ulcerative colitis associated with hypereosinophilic syndrome/chronic eosinophilic leukemia. Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:16 Topics: Benzamides; Chronic Disease; Colitis, Ulcerative; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Piperazines; Pyrimidines; Treatment Outcome; Young Adult	2011
Development of a population-based cost-effectiveness model of chronic graft-versus-host disease in Spain. Clinical therapeutics, 2012, Volume: 34, Issue:8 Topics: Antibodies, Monoclonal, Murine-Derived; Benzamides; Chronic Disease; Computer Simulation; Cost-Benefit Analysis; Drug Costs; Graft vs Host Disease; Health Care Costs; Health Care Rationing; Health Services Needs and Demand; Humans; Imatinib Mesylate; Immunosuppressive Agents; Models, Economic; National Health Programs; Needs Assessment; Photopheresis; Piperazines; Pyrimidines; Quality-Adjusted Life Years; Rituximab; Spain; Time Factors; Treatment Outcome	2012
Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease. The American journal of pathology, 2012, Volume: 181, Issue:5 Topics: Animals; Benzamides; Chronic Disease; Dermis; Disease Models, Animal; Drug Therapy, Combination; Female; Fibrosis; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Mice; Mice, Inbred BALB C; Middle Aged; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Scleroderma, Systemic; Signal Transduction	2012
Successful long-term use of imatinib mesylate in pediatric patients with sclerodermatous chronic GVHD. Pediatric transplantation, 2012, Volume: 16, Issue:8 Topics: Adolescent; Benzamides; Chronic Disease; Creatinine; Drug Administration Schedule; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Immunosuppressive Agents; Male; Piperazines; Pyrimidines; Scleroderma, Systemic; Time Factors; Treatment Outcome	2012
Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. Blood, 2012, Dec-13, Volume: 120, Issue:25 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Benzamides; Child; Child, Preschool; Chronic Disease; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Localized; Scleroderma, Systemic; Skin; Young Adult	2012
Imatinib-induced amelioration of neurologic deficits in a rare case of simultaneous association of missed multiple sclerosis and chronic myeloblastic leukemia. Multiple sclerosis (Houndmills, Basingstoke, England), 2013, Volume: 19, Issue:9 Topics: Adult; Antineoplastic Agents; Benzamides; Brain; Chronic Disease; Humans; Imatinib Mesylate; Leukemia; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Piperazines; Pyrimidines	2013
Sti571-induced Stevens-Johnson Syndrome. British journal of haematology, 2002, Volume: 119, Issue:1 Topics: Antineoplastic Agents; Benzamides; Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Stevens-Johnson Syndrome	2002
Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia. American journal of ophthalmology, 2003, Volume: 135, Issue:3 Topics: Antineoplastic Agents; Benzamides; Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retinal Hemorrhage; Retinal Neoplasms; Visual Acuity	2003
Fighting leukemia. Survival rates have tripled thanks to new, more effective treatments. Mayo Clinic women's healthsource, 2003, Volume: 7, Issue:5 Topics: Acute Disease; Age Factors; Antineoplastic Agents; Benzamides; Chronic Disease; Cladribine; Humans; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines; Survival Rate	2003
Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. Transplantation, 2003, Apr-27, Volume: 75, Issue:8 Topics: Animals; Benzamides; Chronic Disease; Cyclosporine; Enzyme Inhibitors; Graft Rejection; Imatinib Mesylate; Immunosuppressive Agents; Kidney; Kidney Diseases; Kidney Transplantation; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Rats; Rats, Inbred Strains; Rats, Inbred WF; Receptors, Platelet-Derived Growth Factor; Transplantation, Homologous; Transplantation, Isogeneic	2003
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chronic Disease; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fibrinolytic Agents; Humans; Imatinib Mesylate; Male; Medical Records Systems, Computerized; Middle Aged; Myeloproliferative Disorders; Piperazines; Pyrimidines; Quinazolines; Retrospective Studies; Survival Analysis	2003
[Chronic myeloproliferative diseases. Diagnosis and therapy]. Der Internist, 2003, Volume: 44, Issue:8 Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Transplantation; Chronic Disease; Diagnosis, Differential; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Enzymologic; Humans; Hydroxyurea; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Myelodysplastic Syndromes; Myeloproliferative Disorders; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Proteins	2003
Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission. Haematologica, 2004, Volume: 89, Issue:8 Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2004
Every case of essential thrombocythemia should be tested for the Philadelphia chromosome. American journal of hematology, 2005, Volume: 78, Issue:1 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Chronic Disease; Diagnosis, Differential; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Thrombocythemia, Essential	2005
Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy, 2005, Volume: 25, Issue:3 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Chronic Disease; Cost-Benefit Analysis; Decision Support Techniques; Health Care Costs; Humans; Imatinib Mesylate; Insurance, Health, Reimbursement; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Markov Chains; Monte Carlo Method; Piperazines; Pyrimidines	2005
Late-onset marrow aplasia due to imatinib in newly diagnosed chronic phase chronic myeloid leukaemia. Leukemia research, 2005, Volume: 29, Issue:6 Topics: Anemia, Aplastic; Benzamides; Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Malaysia; Male; Middle Aged; Pancytopenia; Piperazines; Pyrimidines; Singapore; Time Factors	2005
The hypereosinophilic syndrome: idiopathic or not, that is the question. Haematologica, 2005, Volume: 90, Issue:5 Topics: Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 4; Chronic Disease; Clone Cells; Diagnosis, Differential; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Lymphoproliferative Disorders; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Staurosporine; T-Lymphocyte Subsets	2005
Isolated central nervous system relapse in patients with chronic myeloid leukemia on imatinib mesylate. Leukemia & lymphoma, 2005, Volume: 46, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Central Nervous System Neoplasms; Chronic Disease; Fatal Outcome; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Recurrence; Remission Induction	2005
Chronic eosinophilic leukemia with the FIP1L1-PDGFRalpha fusion gene in a patient with a history of combination chemotherapy. International journal of hematology, 2006, Volume: 83, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Lymphoma, Non-Hodgkin; Male; Molecular Sequence Data; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sequence Analysis, DNA	2006
Inhibition of SCF attenuates peribronchial remodeling in chronic cockroach allergen-induced asthma. Laboratory investigation; a journal of technical methods and pathology, 2006, Volume: 86, Issue:6 Topics: Administration, Intranasal; Allergens; Animals; Asthma; Benzamides; Bronchi; Bronchial Hyperreactivity; Chemokine CCL17; Chemokines, CC; Chronic Disease; Cockroaches; Eosinophils; Fibrosis; Hydroxyproline; Imatinib Mesylate; Lung; Mice; Mice, Inbred BALB C; Neutralization Tests; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Factor	2006
Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR/ABL rearrangement. Cancer genetics and cytogenetics, 2006, Volume: 167, Issue:1 Topics: Aged; Antineoplastic Agents; Benzamides; Blood Platelets; Bone Marrow Cells; Cells, Cultured; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Chronic Disease; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Piperazines; Pyrimidines; Quinazolines; Thrombocythemia, Essential; Time Factors; Translocation, Genetic; Treatment Outcome	2006
Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes, chromosomes & cancer, 2006, Volume: 45, Issue:10 Topics: Aged; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Benzamides; Cell Cycle Proteins; Chromosomes, Human, Pair 4; Chromosomes, Human, Pair 9; Chronic Disease; DNA Mutational Analysis; Female; Gene Expression Regulation, Neoplastic; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Intracellular Signaling Peptides and Proteins; Molecular Sequence Data; Nerve Tissue Proteins; Oncogene Proteins, Fusion; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction	2006
Imatinib-induced cytogenetic remission in chronic eosinophilic leukaemia. Internal medicine journal, 2006, Volume: 36, Issue:8 Topics: Benzamides; Chronic Disease; Cytogenetic Analysis; Eosinophilia; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction	2006
Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia. Haematologica, 2006, Volume: 91, Issue:8 Topics: Acute Disease; Adult; Antineoplastic Agents; Benzamides; Chronic Disease; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Graft vs Host Disease; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Retrospective Studies; Stem Cell Transplantation; Time Factors; Transplantation, Homologous	2006
Pulmonary arterial hypertension and chronic myeloproliferative disorders. American journal of respiratory and critical care medicine, 2006, Sep-01, Volume: 174, Issue:5 Topics: Benzamides; Chronic Disease; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Myeloproliferative Disorders; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2006
Successful treatment with imatinib mesylate in a case of chronic myeloproliferative disorder with a t(5;12)(q33;p13.1) without eosinophilia. Cancer genetics and cytogenetics, 2006, Volume: 169, Issue:2 Topics: Benzamides; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 5; Chronic Disease; Eosinophilia; Humans; Imatinib Mesylate; Male; Middle Aged; Myeloproliferative Disorders; Piperazines; Pyrimidines; Translocation, Genetic	2006
Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy. Leukemia, 2007, Volume: 21, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 5; Chronic Disease; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Oncogene Proteins, Fusion; Piperazines; Primary Myelofibrosis; Pyrimidines; Transcription, Genetic; Translocation, Genetic	2007
FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells. Leukemia, 2007, Volume: 21, Issue:3 Topics: AC133 Antigen; Antigens, CD; Antigens, CD34; Antineoplastic Agents; Benzamides; Cell Lineage; Chronic Disease; Clone Cells; Drug Resistance; Eosinophils; Erythrocytes; Fusion Proteins, bcr-abl; Glycophorins; Glycoproteins; Granulocytes; Hematopoietic Stem Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunophenotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Subsets; Megakaryocytes; Monocytes; mRNA Cleavage and Polyadenylation Factors; Myeloid Cells; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Peptides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Tumor Stem Cell Assay; X Chromosome Inactivation	2007
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood, 2007, Jun-01, Volume: 109, Issue:11 Topics: Antineoplastic Agents; Benzamides; Chronic Disease; DNA Primers; Exons; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Kinetics; mRNA Cleavage and Polyadenylation Factors; Piperazines; Polymerase Chain Reaction; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Time Factors; Treatment Outcome; United Kingdom	2007
A case report of therapeutic leukapheresis in an adult with chronic myelogenous leukemia presenting with hyperleukocytosis and leukostasis. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2007, Volume: 11, Issue:2 Topics: Adult; Antineoplastic Agents; Benzamides; Blood Viscosity; Chronic Disease; Humans; Imatinib Mesylate; Leukapheresis; Leukemia, Myeloid; Leukocytosis; Leukostasis; Male; Piperazines; Pyrimidines; Retinal Hemorrhage	2007
Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Cancer research, 2007, Apr-15, Volume: 67, Issue:8 Topics: Benzamides; Cell Differentiation; Cell Growth Processes; Chronic Disease; Enzyme Activation; Hematopoietic Stem Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; mRNA Cleavage and Polyadenylation Factors; Myeloid Cells; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; STAT5 Transcription Factor	2007
A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease. Leukemia, 2007, Volume: 21, Issue:8 Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Benzamides; Chronic Disease; Genetic Testing; Humans; Imatinib Mesylate; Male; Molecular Sequence Data; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2007
Detection of FIP1L1-PDGFRA fusion by FISH. British journal of haematology, 2007, Volume: 138, Issue:3 Topics: Adult; Antineoplastic Agents; Benzamides; Chronic Disease; Gene Deletion; Gene Rearrangement; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction	2007
JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. The Lancet. Oncology, 2007, Volume: 8, Issue:7 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Chronic Disease; DNA Mutational Analysis; Genes, abl; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Pyrimidines	2007
Extramedullary molecular evidence of the 5'KIAA1509/3'PDGFRB fusion gene in chronic eosinophilic leukemia. Leukemia research, 2008, Volume: 32, Issue:2 Topics: Adult; Antineoplastic Agents; Base Sequence; Benzamides; Chronic Disease; Female; Gene Fusion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Molecular Sequence Data; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic	2008
[Physiopathology, diagnosis and treatment of chronic myeloproliferative diseases: discussion]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2007, Jul-10, Volume: 96, Issue:7 Topics: Benzamides; Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Piperazines; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrimidines	2007
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer, 2007, Oct-01, Volume: 110, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chi-Square Distribution; Chromosome Aberrations; Chronic Disease; Cytogenetic Analysis; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Logistic Models; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Piperazines; Prognosis; Pyrimidines; Thrombocytopenia; Treatment Failure; Treatment Outcome	2007
A case of Philadelphia-chromosome positive chronic idiopathic myelofibrosis. Leukemia research, 2008, Volume: 32, Issue:4 Topics: Benzamides; Chronic Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Myeloproliferative Disorders; Philadelphia Chromosome; Piperazines; Primary Myelofibrosis; Pyrimidines	2008
RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood, 2008, Apr-01, Volume: 111, Issue:7 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blast Crisis; Chromosomes, Human; Chronic Disease; Core Binding Factor Alpha 2 Subunit; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Phenotype; Piperazines; Point Mutation; Pyrimidines; Retrospective Studies; Survival Rate; Transcription Factors; Translocation, Genetic; Trisomy	2008
Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia. The Journal of allergy and clinical immunology, 2008, Volume: 121, Issue:4 Topics: Amino Acid Sequence; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Base Sequence; Benzamides; Chronic Disease; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; Molecular Sequence Data; mRNA Cleavage and Polyadenylation Factors; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recombinant Fusion Proteins	2008
Successful treatment of chronic myeloproliferative disease-unclassifiable (CMPD-U) with no chromosomal abnormalities by imatinib mesylate. Internal medicine (Tokyo, Japan), 2008, Volume: 47, Issue:8 Topics: Benzamides; Chromosome Aberrations; Chronic Disease; Genes, abl; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Myeloproliferative Disorders; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Treatment Outcome	2008